Ryvu Therapeutics S.A. (RVU.WA) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. RVU.WA files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.58% | 30.00% | Pass |
| Interest-bearing investments | 24.93% | 30.00% | Pass |
| Non-permissible income | 8.18% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 32.55% | 33.00% | Pass |
| Interest-bearing investments | 46.17% | 33.00% | Fail |
| Non-liquid assets | 49.11% | at least 20.00% | Pass |
| Non-permissible income | 8.18% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 32.55% | 33.33% | Pass |
| Cash + interest-bearing securities | 46.17% | 33.33% | Fail |
| Accounts receivable | 50.89% | 33.33% | Fail |
| Non-permissible income | 8.18% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 32.55% | 33.33% | Pass |
| Cash + interest-bearing securities | 46.17% | 33.33% | Fail |
| Accounts receivable | 50.89% | 50.00% | Fail |
| Non-permissible income | 8.18% | 5.00% | Fail |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 10.39% | 33.00% | Pass |
| Cash + interest-bearing securities | 14.74% | 33.00% | Pass |
| Accounts receivable | 1.51% | 33.00% | Pass |
| Non-permissible income | 8.18% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 8.16% | 33.00% | Pass |
| Cash + interest-bearing securities | 11.58% | 49.00% | Pass |
| Accounts receivable | 1.18% | 49.00% | Pass |
| Non-permissible income | 8.18% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 8.16% | 33.33% | Pass |
| Cash + interest-bearing securities | 11.58% | 33.33% | Pass |
| Accounts receivable | 12.76% | 49.00% | Pass |
| Non-permissible income | 8.18% | 5.00% | Fail |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 48.00 | NEUTRAL |
| Stochastic %K (14) | 21.85 | NEUTRAL |
| CCI (20) | -76.64 | NEUTRAL |
| Williams %R (14) | -78.15 | NEUTRAL |
| MACD (12,26,9) | -0.18 | SELL |
| ROC (10) | -7.29 | SELL |
| Momentum (10) | -1.34 | SELL |
| EMA (10) | 17.47 | SELL |
| SMA (10) | 17.48 | SELL |
| EMA (20) | 17.39 | SELL |
| SMA (20) | 17.78 | SELL |
| EMA (30) | 17.16 | SELL |
| SMA (30) | 17.19 | SELL |
| EMA (50) | 17.02 | BUY |
| SMA (50) | 16.32 | BUY |
| EMA (100) | 17.97 | SELL |
| SMA (100) | 17.45 | SELL |
| EMA (200) | 21.02 | SELL |
| SMA (200) | 21.51 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia. In addition, the company's early pipeline candidates include candidates in the areas of kinases, synthetic lethality, immunometabolism, and immuno-oncology. It has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted therapies based on Ryvu's STING agonist technology. The company was formerly known as Selvita S.A. and changed its name to Ryvu Therapeutics S.A. in October 2019. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.